- Poster presentation
- Open Access
Community- vs. healthcare-associated Clostridium difficile infections, Finland, 2008-2013: incidence, case fatality and genotypes
© Kotila et al; licensee BioMed Central Ltd. 2015
- Published: 16 June 2015
- Case Fatality
- Clostridium Difficile Infection
- Clostridium Difficile
- Acute Care Hospital
- Annual Incidence Rate
Clostridium difficile is not restricted to acute care hospitals.
The objective was to evaluate the incidence, case fatality and trends of community- (CA) vs. healthcare-associated (HA) C. difficile infections (CDI) in Finland during 2008-2013.
CDI cases were identified from the National Infectious Disease Register to which all microbiology laboratories have notified toxin-positive C. difficile findings since 2008. Using cases’ national identity codes, dates of death were obtained from the National Population Information System and data of the National Hospital Discharge Register was used to classify cases as CA or HA. PCR ribotyping results were obtained from the reference laboratory.
A total of 33,303 CDI cases were identified; 10,874 (32.7%) were CA (33.7/100,000). The average annualised incidence rate of CA-CDI was significantly higher among persons aged 0-44 years, whereas in older age groups HA-CDI rates were higher. CA-CDI rate was higher in females than in males, especially in persons aged 15-44 years. The overall annual incidence rate of CDI decreased significantly, from 120.0/100,000 in 2008 to 93.4 in 2013, related to the decreasing rate of HA-CDI. 30-day case fatality was lower in CA-CDI than in HA-CDI in all age groups. Altogether 1211 C. difficile isolates were linked with CDI cases (3.6%), of which 268 were CA and 943 HA. In both groups the most frequent PCR ribotype was 027.
While HA-CDI rate decreased, likely in response to improved infection control and increased awareness, CA-CDI rate remained stable. Preventive efforts, such as antimicrobial stewardship campaigns, should also cover long-term care and out-patient settings.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.